Put Arrhythmia Warnings for Lamotrigine in Context

June 2021

A new FDA warning will spur questions about the risk of serious arrhythmias with lamotrigine (Lamictal).

Labeling now cautions to weigh lamotrigine risks and benefits in patients with ischemic CV damage (prior MI, etc)...structural or functional disease (heart failure, AV block, etc)...or multiple CV risks.

It stems from lab data showing that lamotrigine’s effects on cardiac sodium channels could widen the QRS interval...and from case reports linking lamotrigine to ECG changes or cardiac arrest.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

COVID-19 Answer Questions About COVID-19 Vaccines for Kids 12 and Up
Psychiatry Be Alert for PTSD Linked to the COVID-19 Pandemic
Substance Use Disorder Improve Access to Buprenorphine for Opioid Use Disorder
COVID-19 Help Build Trust in COVID-19 Vaccines
COVID-19 Clarify the Role of Home Tests for COVID-19
Warnings Put Arrhythmia Warnings for Lamotrigine in Context
Communication Be Ready to Help People Who Are Deaf or Hard of Hearing
Ear, Nose & Throat Give Advice on How to Treat and Prevent Nosebleeds
Rosacea Sort Through Topical Meds for Rosacea
Liver Disease Don’t Jump to Albumin for Decompensated Liver Disease
Radiology Optimize Safety With IV Contrast Agents
Dosing Standardize Processes for Med Dosing in Obesity
Cystic Fibrosis Look for Cystic Fibrosis Patients Taking Bronchitol

Put Arrhythmia Warnings for Lamotrigine in Context

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents